What are the recommended management steps for a patient with anxiety and mood instability who is taking lamotrigine but is dissatisfied with the medication?

Management of Patient Dissatisfied with Lamotrigine for Anxiety and Mood Instability

Your patient's dissatisfaction with lamotrigine after only a brief trial is premature—therapeutic effects require 6–8 weeks of titration to reach the target dose of 150–300 mg/day, and a dose of 50 mg/day is sub-therapeutic for mood stabilization. 1

Immediate Assessment Priorities

Before modifying the medication regimen, you must:

• Confirm the current lamotrigine dose and duration of therapy. If the patient has been on treatment for only 3 weeks or remains below 150 mg/day, the medication has not been adequately trialed. 1

• Screen for ongoing cannabis or substance use, as this is a primary barrier to treatment response and must be addressed before attributing failure to the medication. 1 Ongoing substance use can mimic or exacerbate anxiety and mood instability, confounding your assessment.

• Explore specific reasons for dissatisfaction. Is it side effects, lack of perceived benefit, or impatience with the titration schedule? This distinction guides your next steps. 2, 3

Optimizing Lamotrigine Therapy

If the patient is willing to continue:

• Titrate lamotrigine to the therapeutic range of 150–300 mg/day using a standard schedule: increase by 25–50 mg every 1–2 weeks. 1 This gradual escalation minimizes the risk of serious rash while achieving efficacy for mood stabilization.

• Do not label the treatment as a failure if dosing remains sub-therapeutic or the trial duration is less than 6–8 weeks. 1 Premature discontinuation is a common pitfall that deprives patients of potential benefit.

• Monitor weekly during the first month to assess adherence, side effects (especially rash), and any ongoing substance use. 1 Use standardized tools like the PHQ-9 for depression and GAD-7 for anxiety at each visit to objectively track symptom changes. 1

• If manic symptoms emerge during titration, add a proven mood stabilizer such as lithium or valproate rather than discontinuing lamotrigine. 1 This augmentation strategy addresses emergent mania while preserving the antidepressant effects of lamotrigine.

Addressing Anxiety Symptoms During Titration

While lamotrigine reaches therapeutic levels:

• Hydroxyzine is appropriate for acute anxiety episodes but should not serve as the sole long-term therapy. 1 It is safer than benzodiazepines for longer-term use due to lower abuse potential and cognitive impairment risk. 1

• Benzodiazepines must be prescribed for limited duration only (e.g., 2–4 weeks) because of dependence risk, abuse potential, and cognitive side effects. 3, 1 If the patient is already on a benzodiazepine, plan for tapering once lamotrigine reaches therapeutic effect.

• Incorporate cognitive-behavioral therapy (CBT) or behavioral activation as adjunctive treatment. 1 Psychotherapy is a core component for mild-to-moderate anxiety and enhances medication response. 3

Cannabis Cessation as a Treatment Priority

Immediate cannabis cessation should be strongly counseled using specific behavioral strategies and close monitoring. 1 Cannabis use is a primary treatment barrier that must be addressed before attributing non-response to medication factors. 1

• Provide structured cessation support, including identifying triggers, developing coping strategies, and scheduling frequent follow-up (weekly initially). 1

• Rule out ongoing substance use as a cause of treatment failure before making any medication changes. 1 Persistent cannabis use can perpetuate anxiety and mood instability regardless of pharmacotherapy.

When to Modify Treatment

If symptoms persist despite confirmed adherence, cannabis abstinence, and 8 weeks of optimized lamotrigine therapy at 150–300 mg/day, then modify the treatment plan. 1, 2

Options include:

• Adding a psychological intervention (individual CBT if group therapy has not been tried). 3, 1

• Switching to an SSRI if anxiety is the predominant symptom and bipolar disorder has been ruled out. SSRIs should be chosen based on side effect profiles and patient preference. 3 Avoid antidepressant monotherapy if bipolar disorder is confirmed, as it may destabilize mood. 1

• Referring to psychiatry for complex medication management or treatment-resistant cases. 1 Specialist input can guide advanced pharmacologic strategies such as augmentation with lithium, valproate, or atypical antipsychotics. 4, 5

Common Pitfalls to Avoid

• Do not discontinue lamotrigine prematurely due to perceived lack of effect when the dose is sub-therapeutic or the trial duration is inadequate. 1

• Do not ignore substance use as a confounding factor. Cannabis and other substances must be addressed as primary treatment barriers. 1

• Do not rely solely on benzodiazepines or hydroxyzine for long-term anxiety management. These are adjuncts, not substitutes for definitive mood stabilization and psychotherapy. 1, 3

• Patients with anxiety often avoid follow-through on referrals; proactively address barriers to care such as transportation, cost, or fear of stigma. 3, 1

Structured Follow-Up Plan

• Weekly visits during the first month to assess adherence, side effects, and cannabis use status. 1

• Monthly reassessment thereafter using PHQ-9 and GAD-7 to quantify symptom change. 1

• After 8 weeks of optimized therapy, if symptom reduction and satisfaction remain poor despite good compliance and abstinence, escalate to additional interventions (add psychotherapy, change medications, or refer to psychiatry). 1, 2, 3